DHHS Adult ARV Guidelines
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir and induction of CYP3A4 by mavacamten
Clinical Effects
Potential increased risk of mavacamten adverse effects
Management
If initiating lenacapavir in patients stable on mavacamten, reduce mavacamten dose by one level (e.g. 15 mg to 10 mg, 10 mg to 5 mg, 5 mg to 2.5 mg). If initiating mavacamten in patients stable on lenacapavir, use typical starting dose (5 mg daily).
Info Source
